Last edition
News about "SRI-4 Response"
Johnson & Johnson's Nipocalimab Shows Sustained Disease Reduction in Lupus Phase 2 Study
The monoclonal antibody met its primary endpoint in the JASMINE trial and demonstrated continued improvements in disease activity through 52 weeks in adults with moderate-to-severe systemic lupus erythematosus.
SRI-4 Response | 04/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members